Fri, Jul 25, 2014, 5:58 AM EDT - U.S. Markets open in 3 hrs 32 mins

Recent

% | $
Click the to save as a favorite.

Arrowhead Research Corp. Message Board

  • investron@ymail.com investron Dec 4, 2013 3:55 PM Flag

    Webcast Takeaways

    - ARWR has transformed from retail to institution. That's why the short attack today that might have worked on clueless retail investors fell totally flat.

    - ALNY goes from $10 to $60 on miniscule disease, just imagine what ARWR will get to in 2014 on Hep B. That's why no rush to sell or partner.

    - ARWR has all the ingredients to become the giant of RNAi. Good summary of these acquired from Roche and very intriguing insights into that deal of the century. (Once again, Roche put more than $500 million into this that today would cost in excess of $1 billion in my estimation.)

    - DPC is the most flexible and powerful delivery extant and ARC-520 will highlight that fact in a blinding neon light in the coming P2s.

    I will be putting what money I can find into this company, consistent with developments.

    Frankly, I view this as the opportunity of the lifetime.

    12 mo. price target north of $100.

    Shorts are welcome to increase the number of shares. It'll be a while before new shares will be made available to the market and at much higher prices as co has all the money it wants right now to do what they want through 2016.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARWR
11.44-0.22(-1.89%)Jul 24 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.